comparemela.com

Latest Breaking News On - Immediate immunity - Page 9 : comparemela.com

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

22.02.2022 - Annual Product Sales for 2021 Increased 25% over 2020PORTLAND, Maine, Feb. 22, 2022 (GLOBE NEWSWIRE) - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets .

Raffael Lichdi, DVM Joins ImmuCell s Sales & Marketing Team

Raffael Lichdi, DVM Joins ImmuCell s Sales & Marketing Team
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain®

ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain®
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

ImmuCell Closes $4,250,000 Equity Financing

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ImmuCell Closes $4,250,000 Equity Financing ImmuCell CorporationApril 14, 2021 GMT PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment. On April 14, 2021, the Company issued the aggregate of 515,156 common shares at $8.25 per share directly to its largest stockholder (the Pessin family) and several other investors, raising gross proceeds of $4,250,037, with minimal closing costs. These shares have been registered under the Company’s effective shelf registration statement on Form S-3.

ImmuCell Announces Restructuring of its Bank Debt

Share: PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) ImmuCell Corporation (Nasdaq: ICCC) ( ImmuCell or the Company ), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a restructuring of its bank debt. Today, the Company secured a $1.5 million loan from its existing lender, Gorham Savings Bank, with a seven-year term and amortization at 3.5% per annum. Approximately $624,000 of the proceeds were used to pay down the outstanding balance on its mortgage loan with Gorham Savings Bank. In connection with that pay-down, the bank released the $1.4 million in funds that had been held by the bank in a restricted collateral account since the Company s March 2020 financing. The remaining proceeds of approximately $876,000 are available to pay closing costs and for general working capital purposes.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.